Plain-English translation of NCT04852588 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a minimally invasive procedure to sample chest lymph nodes — called endobronchial ultrasound-guided fine needle aspiration or transesophageal ultrasound-guided fine needle aspiration — helps doctors better understand the extent of cancer in your lymph nodes before radiation treatment. The radiation treatment being used is called SABR (stereotactic ablative radiotherapy), which is a newer, more precise form of radiation that delivers high doses to small tumors. The goal is to see if this lymph node sampling procedure gives doctors important information that imaging scans alone cannot provide.
Currently, doctors use imaging scans alone to determine whether cancer has spread to lymph nodes in patients being treated with curative-intent radiation. This trial exists to find out if directly sampling suspicious lymph nodes provides doctors with more accurate information to plan better treatment and improve outcomes.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will undergo a minimally invasive procedure where doctors use an ultrasound-guided needle to sample small pieces of suspicious lymph nodes in your chest — this is done through your mouth or throat without surgery. After the sampling procedure, you will proceed with your planned radiation treatment (SABR). The study will compare the information from your lymph node samples with what doctors see on imaging scans to determine how useful the procedure is for planning your treatment.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Canada